A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Glofitamab-1

This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.

2024-01-01

2027-12-31

2028-12-31

Recruiting

20

Inclusion Criteria: 1. Histologically-confirmed DLBCL 2. Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy 3. Participants must have measurable disease Exclusion Criteria: 1. Pregnancy or breastfeeding 2. Patient with known active infection, or reactivation of a latent infection 3. Patient with active autoimmune disease or immune deficiency 4. severe organ failure：LVEF\<40%；DLCO\<40%；eGFR\<30ml/min；Bilirubin≥3ULN 5. Patients who are dependent on the sponsor, the investigator or the trial site

{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '3 Years', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}

2024-07-01